市場調查報告書
商品編碼
1029301

全球阿爾茨海默病市場:行業趨勢、市場份額、規模、增長率、機會和預測(2021-2026)

Alzheimer's Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日期: | 出版商: IMARC Services Private Limited | 英文 140 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

預計 2020 年全球阿爾茨海默病治療市場將達到 63.4 億美元,並在 2021 年至 2026 年間以 6.50% 的複合年增長率增長。

阿爾茨海默病是一種以大腦多個區域的神經細胞退化為特徵的疾病。它會導致記憶、語言、思維和行為等認知功能的惡化。阿爾茨海默病的常見症狀包括抑鬱、記憶力減退、約束力下降以及思維和推理問題。阿爾茨海默病的診斷包括體格檢查、血液檢查、腦成像檢查、精神狀態和神經心理檢查。根據結果,醫生開出各種藥物來緩解症狀。阿爾茨海默病藥物會影響神經遞質的功能,神經遞質是參與大腦神經細胞之間信息傳遞的化學物質。

阿爾茨海默病治療的市場趨勢

  • 糖尿病、肥胖、心臟病、高血壓、久坐的生活方式、不健康的飲食習慣、吸煙等被認為是增加患阿爾茨海默病可能性的因素。這些疾病、生活方式的增加和老年人口的增加是市場增長的主要因素。此外,大型製藥公司正專注於開發預防疾病和長期改善認知功能的藥物。此外,遠程醫療服務的擴展和在線藥店的普及正在支持市場增長。這些平台使遠程疾病診斷和藥物輸送成為可能。此外,各種阿爾茨海默病治療藥物,如 aducanumab、Solanezumab 和胰島素,目前都處於後期臨床試驗階段。這些藥物的開發有望在未來幾年推動市場增長。

本報告調查了全球阿爾茨海默病藥物市場,並提供有關行業趨勢、市場預測、按藥物類別/分銷渠道/區域進行的市場分析、競爭形勢、主要公司概況等方面的信息。我們還不斷跟蹤和評估流行病對各種最終用途行業的直接和間接影響,同時牢記 COVID-19 的不確定性。

目錄

第一章前言

第二章範圍和調查方法

第 3 章執行摘要

第 4 章介紹

第 5 章全球阿爾茨海默病治療市場

  • 市場概覽
  • 市場表現
  • COVID-19 的影響

第 6 章按藥物類別劃分的市場細分

  • 多奈□齊
  • 加蘭他敏
  • 利凡斯的明
  • 美金剛
  • 其他

第 7 章按分銷渠道劃分的市場細分

  • 醫院藥房
  • 零售藥店
  • 網上商店
  • 其他

第 8 章按地區劃分的市場細分

  • 北美
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞
    • 印度尼西亞
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東/非洲
    • 按國家/地區劃分的市場細分

第 9 章 SWOT 分析

第10章價值鏈分析

第11章波特五力分析

第12章價格分析

第十三章競爭形勢

  • 市場結構
  • 主要公司
  • 主要公司簡介
    • Abbvie Inc.
    • AstraZeneca PLC
    • Biogen Inc.
    • Daiichi Sankyo Company Limited
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • H. Lundbeck A/S
    • F. Hoffmann-La Roche AG
    • Merck & Co. Inc.
    • Novartis AG
    • Ono Pharmaceutical Co. Ltd.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Limited
目錄
Product Code: SR1020F251_Report

The global alzheimer's drugs market reached a value of US$ 6.34 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 6.50% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Alzheimer's is a disease characterized by the degeneration of nerve cells in several areas of the brain. It causes loss of cognitive function, such as memory, language, thinking and behavior. The common symptoms of Alzheimer's include depression, memory impairment, loss of inhibitions, and problems with thinking and reasoning. It is usually diagnosed by performing physical exams, blood tests, brain imaging, and mental status and neuropsychological testing. According to the results, doctors prescribe different medications to alleviate symptoms. Alzheimer's drugs influence the functions of neurotransmitters, the chemicals involved in carrying messages between nerve cells in the brain.

Alzheimer's Drugs Market Trends:

  • Diabetes, obesity, heart diseases and high blood pressure (BP), in confluence with sedentary lifestyles, unhealthy dietary patterns and smoking, are some of the factors known to increase the chances of developing Alzheimer's disease. An increase in the prevalence of these ailments and lifestyle choices among the masses, coupled with the rising geriatric population, represents one of the key factors driving the market growth. Furthermore, the leading pharmaceutical companies are focusing on the development of drugs that prevent the disease and provide long-lasting improvements in cognitive functions. The market growth is further supported by the expansion of telehealth services and the growing traction of online pharmacies. These platforms have enabled disease diagnosis and drug delivery in remote regions. Apart from this, various Alzheimer's drugs are presently under late-stage clinical trials, including Aducanumab, Solanezumab and Insulin. The development of these drugs is anticipated to propel the market growth in the coming years.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global alzheimer's drugs market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

  • Donepezil
  • Galantamine
  • Rivastigmine
  • Memantine
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited. Key Questions Answered in This Report:

  • How has the global alzheimer's drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global alzheimer's drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global alzheimer's drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Alzheimer's Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Donepezil
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Galantamine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Rivastigmine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Memantine
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Stores
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Abbvie Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca PLC
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Biogen Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Daiichi Sankyo Company Limited
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Eisai Co. Ltd.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Eli Lilly and Company
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 H. Lundbeck A/S
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 F. Hoffmann-La Roche AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Novartis AG
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Ono Pharmaceutical Co. Ltd.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12 Pfizer Inc.
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials
      • 13.3.12.4 SWOT Analysis
    • 13.3.13 Teva Pharmaceutical Industries Limited
      • 13.3.13.1 Company Overview
      • 13.3.13.2 Product Portfolio
      • 13.3.13.3 Financials
      • 13.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Alzheimer's Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Alzheimer's Drugs Market: Sales Value (in Billion US$), 2015-2020
  • Figure 3: Global: Alzheimer's Drugs Market: Breakup by Drug Class (in %), 2020
  • Figure 4: Global: Alzheimer's Drugs Market: Breakup by Distribution Channel (in %), 2020
  • Figure 5: Global: Alzheimer's Drugs Market: Breakup by Region (in %), 2020
  • Figure 6: Global: Alzheimer's Drugs Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 7: Global: Alzheimer's Drugs (Donepezil) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 8: Global: Alzheimer's Drugs (Donepezil) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 9: Global: Alzheimer's Drugs (Galantamine) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 10: Global: Alzheimer's Drugs (Galantamine) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 11: Global: Alzheimer's Drugs (Rivastigmine) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 12: Global: Alzheimer's Drugs (Rivastigmine) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 13: Global: Alzheimer's Drugs (Memantine) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 14: Global: Alzheimer's Drugs (Memantine) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 15: Global: Alzheimer's Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 16: Global: Alzheimer's Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 17: Global: Alzheimer's Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 18: Global: Alzheimer's Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 19: Global: Alzheimer's Drugs (Retail Pharmacy) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 20: Global: Alzheimer's Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 21: Global: Alzheimer's Drugs (Online Stores) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 22: Global: Alzheimer's Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 23: Global: Alzheimer's Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 24: Global: Alzheimer's Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 25: North America: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 26: North America: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 27: United States: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 28: United States: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 29: Canada: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 30: Canada: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 31: Asia Pacific: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 32: Asia Pacific: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 33: China: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 34: China: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 35: Japan: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 36: Japan: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 37: India: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 38: India: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 39: South Korea: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 40: South Korea: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 41: Australia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 42: Australia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 43: Indonesia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 44: Indonesia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 45: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 46: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 47: Europe: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 48: Europe: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 49: Germany: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 50: Germany: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 51: France: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 52: France: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 53: United Kingdom: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 54: United Kingdom: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 55: Italy: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 56: Italy: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 57: Spain: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 58: Spain: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 59: Russia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 60: Russia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 61: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 62: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 63: Latin America: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 64: Latin America: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 65: Brazil: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 66: Brazil: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 67: Mexico: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 68: Mexico: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 69: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 70: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 71: Middle East and Africa: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 72: Middle East and Africa: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 73: Global: Alzheimer's Drugs Industry: SWOT Analysis
  • Figure 74: Global: Alzheimer's Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Alzheimer's Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Alzheimer's Drugs Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Alzheimer's Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2021-2026
  • Table 3: Global: Alzheimer's Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2021-2026
  • Table 4: Global: Alzheimer's Drugs Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 5: Global: Alzheimer's Drugs Market: Competitive Structure
  • Table 6: Global: Alzheimer's Drugs Market: Key Players